EDTA: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antidote (chelator) *Dosage Forms: *Routes of Administration: IV/IM *Alternate names: Calcium Disodium Edathamil, Calcium Disodium Edetate, ethyl...") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Asymptomatic or symptomatic lead poisoning, level 20-70 mcg/dL: 1000 mg/m(2)/day IV over 8-12h OR IM in divided doses q8-12 hours | *Asymptomatic or symptomatic lead poisoning, level 20-70 mcg/dL: 1000 mg/m(2)/day IV over 8-12h '''OR''' IM in divided doses q8-12 hours | ||
*Administer with [[dimercaprol]] if level >70 mcg/dL or symptomatic | *Administer with [[dimercaprol]] if level >70 mcg/dL or symptomatic | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 45: | Line 45: | ||
==Comments== | ==Comments== | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::EDTA]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
| Line 53: | Line 69: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Toxicology]] | |||
Latest revision as of 21:57, 20 March 2026
Administration
- Type: Antidote (chelator)
- Dosage Forms:
- Routes of Administration: IV/IM
- Alternate names: Calcium Disodium Edathamil, Calcium Disodium Edetate, ethylenediamine tetraacetic acid, Edetic acid, Edetate calcium
Adult Dosing
- Asymptomatic or symptomatic lead poisoning, level 20-70 mcg/dL: 1000 mg/m(2)/day IV over 8-12h OR IM in divided doses q8-12 hours
- Administer with dimercaprol if level >70 mcg/dL or symptomatic
Pediatric Dosing
- Same as above
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: reduce dose if mild impairment, contraindicated if anuria or active renal disease
- Hepatic dosing: contraindicated in active hepatitis
Contraindications
- Allergy to class/drug
- Anuria, active renal disease
- Active hepatitis
Adverse Reactions
Serious
All listed here are relatively frequent complications
- Hypotension
- Thrombophlebitis
- Fever
- Nephrotoxicity
- Hypersensitivity reaction
Common
- Injection site pain
- Nausea/vomiting
- Myalgia
- Headache
Pharmacology
- Half-life: 20-60min
- Metabolism: Not metabolized
- Excretion: Renal
Mechanism of Action
- Divalent/trivalent metals (especially lead) replace calcium in EDTA forming stable, soluble complexes that are readily excreted
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Lead toxicity | 1000-1500mg/m2/day IV continuous infusion x 5 days | Chelation, do not use as sole agent if encephalopathy | IV | Adult |